Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen’s growth challenges; Novartis’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 22 July 2022, including: Novo Nordisk A/S obesity drugs in US cost-effectiveness spotlight; Biogen, Inc.’s growth challenges; Novartis AG’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Novo Nordisk's Obesity Drugs Exceed ICER’s Cost Effectiveness Thresholds" - Scrip, 18 Jul, 2022.)
(Also see "Without An Alzheimer’s Blockbuster, Biogen Is A Ship Without A Growth Rudder" - Scrip, 20 Jul, 2022.)
(Also see "Novartis Finance Chief Rules Out Large M&A" - Scrip, 19 Jul, 2022.)
(Also see "Pharma Q2 Preview: Demonstrating Resiliency Against A Turbulent Backdrop" - Scrip, 15 Jul, 2022.)
(Also see "MSD’s Asia Pacific Chief On Lagevrio’s Gains In Clinical Utility Amid Paxlovid Luster" - Scrip, 19 Jul, 2022.)